Skip to main content

January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights

View Additional ASH 2018 Coverage

Practice Management

Economic Implications of Inpatient versus Outpatient Autologous Transplant for Patients with Multiple Myeloma

Chase Doyle

Practice Management

Inpatient Costs for Children and Young Adults with Acute Lymphoblastic Leukemia Higher at Specialized Cancer Centers, but for a Good Reason?

Chase Doyle

In the Literature, Oncology

Ibrutinib Superior to Standard Chemoimmunotherapy in Older Patients with CLL

In the Literature, Oncology

Olaparib Maintenance Extends Progression-Free Survival in Advanced Ovarian Cancer

In the Literature, Oncology

Tisagenlecleucel Leads to High Rates of Durable Response in Relapsed, Refractory DLBCL

Oral Rigosertib plus Azacitidine Combination Shows Promising Results in High-Risk Myelodysplastic Syndromes

Chase Doyle

Luspatercept, First-in-Class Erythroid Maturation Agent, Reduces Transfusions in Patients with Low-Risk Myelodysplastic Syndromes

Wayne Kuznar

Multiple Myeloma, Oncology

Elotuzumab, Lenalidomide, and Dexamethasone Combination Demonstrates High Response Rate in High-Risk Smoldering Multiple Myeloma

Chase Doyle

Daratumumab Enhances Remissions When Added to Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Wayne Kuznar

Dual-Specific CAR T-Cell Therapy Targets CD19 and CD22 in Patients with Acute Lymphoblastic Leukemia

Chase Doyle

Page 1 of 3
Results 1 - 10 of 24